RVLP News and Press, RVL Pharmaceuticals plc From 04/03/23

BRIDGEWATER, N.J., April 03, 2023 (GLOBE NEWSWIRE) --  RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”) announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner ...

2023-03-20 12:04:06 ET RVL Pharmaceuticals plc (RVLP) Q4 2022 Earnings Conference Call March 20, 2023 8:30 am ET Company Participants Brian Markison - Chief Executive Officer JD Schaub - Chief Operating Officer Mike DePetris - Chief Financial Officer (interim) ...

2023-03-20 07:07:48 ET RVL Pharmaceuticals plc press release ( NASDAQ: RVLP ): Q4 GAAP EPS of -$0.18 misses by $0.01 . Revenue of $9.81M (+243.0% Y/Y) misses by $2.72M . At December 31, 2022, cash and cash equivalents were $44.5 million and long-term debt had a...

-- RVLP records exceptional year-over-year growth with UPNEEQ ® launch into the medical aesthetics market -- -- Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, over 2021 -- -- Full year 2022 UPNEEQ net product sales of $34.2 mill...

BRIDGEWATER, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, toda...

2023-03-10 17:31:23 ET Amid concerns about smaller pharma and biotech companies' exposure to Silicon Valley Bank ( SIVB ), a number of them have disclosed that they have no relationship with the FDIC-shuttered financial institution . Among the larger ones are Cara Therapeu...

RVL Pharmaceuticals ( NASDAQ: RVLP ) rose 7.7% pre market after it notifies preliminary fourth quarter and full year 2022 net product sales of UPNEEQ of ~$12.1M and $36.5M, respectively. The preliminary fourth quarter 2022 net product sales of UPNEEQ represent a sequential inc...

-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for full year 2022 -- -- Approximately 4,300 cumulative unique medical aesthetics practices had plac...

Summary Today we take our first look at RVL Pharmaceuticals plc, a small ocular-focused concern. RVL Pharmaceuticals plc recently launched the first and only FDA-approved ophthalmic solution to treat low-lying eyelids in adults. Unfortunately, impressive early sales growth has not y...

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a panel presentation and host 1x1...